Tirzepatide as a novel effective and safe strategy for treating obesity: A systematic review and meta-analysis of randomized controlled trials
GLP-1 medications are typically prescribed for long-term use, as weight regain commonly occurs after discontinuation
But it can be an avenue for people who are struggling to get to that next step. This article originally appeared as A Balanced Approach to Weight-Loss Drugs in the March/April 2025 issue of Experience Life.
Remember: this week is temporary
Multiple molecular mechanisms, activated by inflammatory mediators, contribute to the progression of HS.34,35 The prevalence of DT2 is higher in subjects with HS than in the general population.36 HS is also associated with other conditions traditionally linked with obesity, such as metabolic syndrome, polycystic ovarian syndrome, and inflammatory bowel disease,3739 and patients with HS are exposed to higher CVR than the general population.40 Obesity negatively impacts the response of patients to the main treatments for HS (Table S1 additional information).15 Advantages associated with weight loss in patients with obesity and psoriasis or hidradenitis suppurativa In addition to better response to treatments for inflammatory dermatoses, other arguments justify the desirability of patients with obesity and PsO or HS to lose weight